"10.1371_journal.pone.0128807","plos one","2015-06-12T00:00:00Z","C Gianna Hoffman-Luca; Chao-Yie Yang; Jianfeng Lu; Daniel Ziazadeh; Donna McEachern; Laurent Debussche; Shaomeng Wang","University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States of America; Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America; Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America; Sanofi Oncology, Vitry-sue-Seine, France","Conceived and designed the experiments: CGH-L C-YY JL DZ DM SW. Performed the experiments: CGH-L C-YY JL DZ DM. Analyzed the data: CGH-L C-YY JL DZ DM. Contributed reagents/materials/analysis tools: LD. Wrote the paper: CGH-L C-YY SW.","SW is an inventor of SAR405838, which has been licensed by Ascenta and Sanofi for clinical development; patent name “Spiro-oxindole MDM2 antagonists” and US patent number 8,680,132. SW owns stock in Ascenta and receives royalty from the University of Michigan. LD is an employee of Sanofi Oncology. There are no further patents, products in development or marketed products to declare related to this study. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","06","C Gianna Hoffman-Luca","CGHL",7,TRUE,6,5,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
